Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.

Herrero AB, Martín-Castellanos C, Marco E, Gago F, Moreno S.

Cancer Res. 2006 Aug 15;66(16):8155-62.

2.

Role of homologous recombination in trabectedin-induced DNA damage.

Tavecchio M, Simone M, Erba E, Chiolo I, Liberi G, Foiani M, D'Incalci M, Damia G.

Eur J Cancer. 2008 Mar;44(4):609-18. doi: 10.1016/j.ejca.2008.01.003. Epub 2008 Feb 19.

PMID:
18243687
3.

Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).

Romano M, Frapolli R, Zangarini M, Bello E, Porcu L, Galmarini CM, García-Fernández LF, Cuevas C, Allavena P, Erba E, D'Incalci M.

Int J Cancer. 2013 Nov;133(9):2024-33. doi: 10.1002/ijc.28213. Epub 2013 May 25.

4.

Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.

Soares DG, Machado MS, Rocca CJ, Poindessous V, Ouaret D, Sarasin A, Galmarini CM, Henriques JA, Escargueil AE, Larsen AK.

Mol Cancer Ther. 2011 Aug;10(8):1481-9. doi: 10.1158/1535-7163.MCT-11-0252. Epub 2011 May 27.

6.
7.

Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.

Aune GJ, Takagi K, Sordet O, Guirouilh-Barbat J, Antony S, Bohr VA, Pommier Y.

Clin Cancer Res. 2008 Oct 15;14(20):6449-55. doi: 10.1158/1078-0432.CCR-08-0730.

8.

Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.

García MJ, Saucedo-Cuevas LP, Muñoz-Repeto I, Fernández V, Robles MJ, Domingo S, Palacios J, Aracil M, Nieto A, Tercero JC, Benítez J.

Mol Cancer Ther. 2013 Apr;12(4):530-41. doi: 10.1158/1535-7163.MCT-12-0768. Epub 2013 Jan 30.

9.

Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.

Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, Henriques JA, Larsen AK.

Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13062-7. Epub 2007 Jul 26.

10.

Unique features of trabectedin mechanism of action.

Larsen AK, Galmarini CM, D'Incalci M.

Cancer Chemother Pharmacol. 2016 Apr;77(4):663-71. doi: 10.1007/s00280-015-2918-1. Epub 2015 Dec 14. Review.

PMID:
26666647
11.

Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin.

Casado JA, Río P, Marco E, García-Hernández V, Domingo A, Pérez L, Tercero JC, Vaquero JJ, Albella B, Gago F, Bueren JA.

Mol Cancer Ther. 2008 May;7(5):1309-18. doi: 10.1158/1535-7163.MCT-07-2432.

12.
14.

Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives.

Vincenzi B, Napolitano A, Frezza AM, Schiavon G, Santini D, Tonini G.

Pharmacogenomics. 2010 Jun;11(6):865-78. doi: 10.2217/pgs.10.69. Review.

PMID:
20504257
15.

Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair.

Harnicek D, Kampmann E, Lauber K, Hennel R, Cardoso Martins AS, Guo Y, Belka C, Mörtl S, Gallmeier E, Kanaar R, Mansmann U, Hucl T, Lindner LH, Hiddemann W, Issels RD.

Int J Cancer. 2016 Jul 15;139(2):467-79. doi: 10.1002/ijc.30070. Epub 2016 Mar 25.

16.

Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.

Guirouilh-Barbat J, Antony S, Pommier Y.

Mol Cancer Ther. 2009 Jul;8(7):2007-14. doi: 10.1158/1535-7163.MCT-09-0336. Epub 2009 Jul 7.

17.

Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.

Lima M, Bouzid H, Soares DG, Selle F, Morel C, Galmarini CM, Henriques JA, Larsen AK, Escargueil AE.

Oncotarget. 2016 May 3;7(18):25885-901. doi: 10.18632/oncotarget.8292.

19.

Trabectedin mechanism of action and platinum resistance: molecular rationale.

Ray-Coquard I.

Future Oncol. 2017 Oct;13(23s):17-21. doi: 10.2217/fon-2017-0318. Epub 2017 Oct 11. Review.

PMID:
29020822
20.

Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways.

Soares DG, Poletto NP, Bonatto D, Salvador M, Schwartsmann G, Henriques JA.

Biochem Pharmacol. 2005 Jul 1;70(1):59-69.

PMID:
15913564

Supplemental Content

Support Center